---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-016574"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2025-06-26T23:59:59+00:00"
generated_at: "2026-05-18T18:23:47.010728+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# MAIA Biotechnology enters $587,905 stock purchase agreement with Prevail Partners for Phase 3 THIO trial

## Summary
- Total purchase amount up to $587,905; monthly payments equal to 33% of invoices for Phase 3 THIO trial services provided by Prevail affiliate InfoWorks.
- Share price set at 120% of 30-day VWAP; minimum share price of $1.74; maximum shares issuable at minimum price: 337,876.
- Shares are unregistered, issued under Section 4(a)(2); subject to 19.99% blocker and Exchange Cap.
- Proceeds used to fund a multicenter Phase 3 study of THIO sequenced with cemiplimab in advanced NSCLC.

## SEC filing metadata
- accession: 0001641172-25-016574
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2025-06-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000164117225016574/0001641172-25-016574-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000164117225016574/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-016574
- JSON: https://secwatch.observer/filing/0001641172-25-016574.json
- Plain text: https://secwatch.observer/filing/0001641172-25-016574.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.